The Organ Handling of Soluble Klotho in Humans.


Journal

Kidney & blood pressure research
ISSN: 1423-0143
Titre abrégé: Kidney Blood Press Res
Pays: Switzerland
ID NLM: 9610505

Informations de publication

Date de publication:
2019
Historique:
received: 17 04 2019
accepted: 03 06 2019
pubmed: 21 8 2019
medline: 30 1 2020
entrez: 21 8 2019
Statut: ppublish

Résumé

Chronic kidney disease (CKD) reduces both Klotho expression and its shedding into circulation, an effect that accelerates progression and cardiovascular complications. However, the mechanisms that regulate Klotho release by the human kidney are still unknown. We measured plasma Klotho across the kidney, splanchnic organs and lung in 22 patients (71 ± 2 years, estimated glomerular filtration rate [eGFR] 60 ± 5.4 mL/min 1.73 m2) during elective diagnostic cardiac catheterizations. Although the Klotho average renal vein concentrations were remarkably higher (by ∼9%) than arterial values, the kidney removed Klotho (or was at zero balance) in 7 subjects, indicating that the kidney contribution to systemic Klotho is not constant. Klotho fractional enrichment across the kidney was inversely related to plasma sodium (r = 0.43, p = 0.045) and acid uric acid levels (r = 0.38, p = 0.084) and directly, to renal oxygen extraction (r = 0.56, p = 0.006). In multivariate analysis, renal oxygen extraction was the only predictor of the enrichment of Klotho across the kidney, suggesting the dependence of renal Klotho release on tubular hypoxia or oxidative metabolism. Klotho balance was neutral across the lung. In patients with eGFR <60 mL/min, Klotho was also removed by splanchnic organs (single pass fractional extraction ∼11%). The present study identifies kidney oxygen uptake as a predictor of Klotho release, and splanchnic organs as a site for Klotho removal. This study provides new understanding of kidney Klotho release and suggests that modulating kidney oxygen metabolism could increase Klotho delivery, as an option to slow disease progression and blunt organ damage.

Sections du résumé

BACKGROUND BACKGROUND
Chronic kidney disease (CKD) reduces both Klotho expression and its shedding into circulation, an effect that accelerates progression and cardiovascular complications. However, the mechanisms that regulate Klotho release by the human kidney are still unknown.
METHODS METHODS
We measured plasma Klotho across the kidney, splanchnic organs and lung in 22 patients (71 ± 2 years, estimated glomerular filtration rate [eGFR] 60 ± 5.4 mL/min 1.73 m2) during elective diagnostic cardiac catheterizations.
RESULTS RESULTS
Although the Klotho average renal vein concentrations were remarkably higher (by ∼9%) than arterial values, the kidney removed Klotho (or was at zero balance) in 7 subjects, indicating that the kidney contribution to systemic Klotho is not constant. Klotho fractional enrichment across the kidney was inversely related to plasma sodium (r = 0.43, p = 0.045) and acid uric acid levels (r = 0.38, p = 0.084) and directly, to renal oxygen extraction (r = 0.56, p = 0.006). In multivariate analysis, renal oxygen extraction was the only predictor of the enrichment of Klotho across the kidney, suggesting the dependence of renal Klotho release on tubular hypoxia or oxidative metabolism. Klotho balance was neutral across the lung. In patients with eGFR <60 mL/min, Klotho was also removed by splanchnic organs (single pass fractional extraction ∼11%).
CONCLUSIONS CONCLUSIONS
The present study identifies kidney oxygen uptake as a predictor of Klotho release, and splanchnic organs as a site for Klotho removal. This study provides new understanding of kidney Klotho release and suggests that modulating kidney oxygen metabolism could increase Klotho delivery, as an option to slow disease progression and blunt organ damage.

Identifiants

pubmed: 31430745
pii: 000501316
doi: 10.1159/000501316
doi:

Substances chimiques

Uric Acid 268B43MJ25
Sodium 9NEZ333N27
Glucuronidase EC 3.2.1.31
Klotho Proteins EC 3.2.1.31
Oxygen S88TT14065

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

715-726

Informations de copyright

© 2019 The Author(s) Published by S. Karger AG, Basel.

Auteurs

Daniela Picciotto (D)

Department of Internal Medicine, Clinica Nefrologica Dialisi e Trapianto, Genoa University and IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Abitha Murugavel (A)

Department of Internal Medicine, Clinica Nefrologica Dialisi e Trapianto, Genoa University and IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Francesca Ansaldo (F)

Department of Internal Medicine, Clinica Nefrologica Dialisi e Trapianto, Genoa University and IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Gian Marco Rosa (GM)

Clinica delle Malattie Cardiovascolari, Genoa University and IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Antonella Sofia (A)

Department of Internal Medicine, Clinica Nefrologica Dialisi e Trapianto, Genoa University and IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Samantha Milanesi (S)

Department of Internal Medicine, Clinica Nefrologica Dialisi e Trapianto, Genoa University and IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Francesca Viazzi (F)

Department of Internal Medicine, Clinica Nefrologica Dialisi e Trapianto, Genoa University and IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Michela Saio (M)

Department of Internal Medicine, Clinica Nefrologica Dialisi e Trapianto, Genoa University and IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Manrico Balbi (M)

Clinica delle Malattie Cardiovascolari, Genoa University and IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Giacomo Garibotto (G)

Department of Internal Medicine, Clinica Nefrologica Dialisi e Trapianto, Genoa University and IRCCS Ospedale Policlinico San Martino, Genoa, Italy, gari@unige.it.

Daniela Verzola (D)

Department of Internal Medicine, Clinica Nefrologica Dialisi e Trapianto, Genoa University and IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH